Medicine and Dentistry
Patient
100%
Glioblastoma
59%
Bevacizumab
43%
Inpatient
33%
Therapeutic Procedure
33%
Brain Metastasis
27%
Surgery
23%
Assessment
21%
Brain
20%
Evofosfamide
20%
Hypoxia
18%
Neoplasm
18%
Experience
15%
Overall Survival
15%
Neuro-Oncology
14%
Combination Therapy
14%
Diagnosis
13%
Progression Free Survival
13%
Lesion
12%
Surgical Infection
12%
Craniopharyngioma
12%
Histiocytic Sarcoma
12%
Endometriosis
12%
Metastatic Carcinoma
12%
Neurosyphilis
12%
Protein
12%
Sciatic Nerve
12%
Interleukin 4 Receptor
12%
Receptor
12%
Oligoastrocytoma
12%
Subdural Hematoma
12%
Breast Cancer
12%
Sacituzumab Govitecan
12%
Craniotomy
11%
Recurrent Disease
11%
Immunotherapy
11%
Element
11%
Analysis
9%
Cyst
9%
Diseases
8%
Obstetric Delivery
8%
Survival
8%
Radiation Therapy
8%
Bone Graft
8%
Proteomics
8%
Senescence
7%
Hazard Ratio
7%
Adverse Event
7%
Biological Marker
7%
Complication
7%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
44%
Bevacizumab
35%
Evofosfamide
17%
Neoplasm
14%
Radiation
12%
Interleukin 4 Receptor
12%
Receptor
12%
Astrocytoma
12%
Sacituzumab Govitecan
12%
Brain Metastasis
12%
Immunotherapy
11%
Diseases
10%
Survival
10%
Overall Survival
8%
Progression Free Survival
8%
Hypoxia
7%
Adverse Event
7%
Mouse Model
7%
Glioma
6%
Nude Mouse
6%
Nude Rat
6%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
20%
Radiation
12%
Volume
12%
Growth
12%
Interleukin-4 Receptor
12%
Dose
11%
Magnetic Resonance Imaging
9%
Overall Survival
8%
Development
8%
Senescence
7%
Progression Free Survival
7%
Survival
6%
Nude Mouse
6%
Clinical Trial
6%
Density
6%
Nude Rat
6%
